Waters Stock (NYSE:WAT), Trade Ideas

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Biotech

Large Cap

Mid Cap

Health Care

Small Cap

Small Business

Analyst Ratings

Tech

General

AVTR

WUXIF

Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.

Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks

Earnings

Equities

News

Guidance

Markets

Waters Corporation beats Q4 earnings estimates, outlining mixed regional sales performance and cautious outlook for 2024.

Waters Q4 Earnings Beats Estimates, CEO Touts Strong Execution In Tough Market Conditions

Penny Stocks

Intraday Update

Movers

Trading Ideas

AORT

BURL

FUSN

GOGL

HIBB

PLSE

Telecom Argentina Stet - France Telecom S.A.

U.S. stocks traded lower, with the Dow Jones falling around 90 points on Tuesday.

Agilent Posts Upbeat Results, Joins Burlington Stores, Hibbett And Other Big Stocks Moving Higher On Tuesday

Waters Corp

Energous Corp

WATERMARK LODGING TRUST A by Watermark Lodging Trust Inc.

WATCHES OF SWITZERLAND G by Watches of Switzerland Group PLC

Watches of Switzerland Group PLC

WATER INTELLIGENCE PLC by Water Intelligence PLC

Water Intelligence PLC

WATER OASIS GROUP LTD by Water Oasis Group Ltd.

Water Oasis Group Ltd

WATER TECH INTL by Water Technologies International,Inc.

Water Technologies International Inc

WATER WAYS TECHS INC by WATER WAYS TECHNOLOGIES INC

Water Ways Technologies Inc

WATERPURE INTL INC by WaterPure International, Inc.

WaterPure International Inc

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop Inc

Waterloo Brewing Ltd

Waterstone Financial, Inc. - Common Stock

Waterstone Financial Inc

Watsco Inc

Watts Co Ltd

Watts Water Technologies, Inc. Class A Common Stock

Watts Water Technologies Inc

WIIM

ILMN

Shares of life sciences tools stocks are trading higher following strong earnings from Danaher.

<ul>
<li>New line of GTxResolve&#x2122; Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of cell &amp; gene-based therapeutics.</li>
<li>Reduces problematic non-specific binding, minimizes mobile phase method development challenges, and provides higher throughput separation efficiency.</li>
<li>Increases resolution up to 50% for components present within mRNA, lipid nanoparticles (LNP), and viral vectorsi&nbsp;for more confident measurement of critical quality attributes tied to safety, stability, and potency.</li>
</ul>
MILFORD, Mass., April 22, 2024 /PRNewswire/ --&nbsp;Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak&#x2122; Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell &amp; gene, mRNA and LNPs.
Waters GTxResolve Premier SEC Columns support the growing demand for mRNA, LNP, and viral-vector-based therapies.
"The pipeline of nucleic acid therapeutics continues to grow at a double-digit paceii as developers strive to submit new investigational drug filings and complete their first in-human trials. The new Waters GTxResolve Premier SEC Columns supports the growing demand for mRNA, lipid nanoparticle, and viral vector-based therapies with columns that are more robust and provide higher efficiency," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation. "These SEC columns help to standardize measurements needed to fulfill biological license applications, achieve accelerated approvals, and establish effective release testing strategies."
SEC has emerged as an important platform analytical technique, but existing technologies require extensive column conditioning, consume large amounts of sample, and require lengthy run times to resolve impurities, making them an imperfect solution. Waters GTxResolve Premier SEC 1000Å 3 µm Columns address those challenges by providing higher sensitivity, resolution, and throughput by combining novel particle technology with low adsorption MaxPeak Premier HPS Technology. They make it possible for scientists to assess drug safety and efficacy more quickly and expedite the development of gene-based therapeutics and vaccines that are both more efficacious and accessible to patients globally.
"RNA lipid nanoparticles are analytically complex therapeutics. Traditional batch analysis techniques only discern information of the drug product as a whole and fail to detect the subtle difference in particle size populations and corresponding compositional variations therein," said Adam Crowe, Analytical Development Manager, Precision Nanosystems. "SEC analyses afforded by these new column technologies are promising because they have shown separations of LNP populations that can be coupled with online or offline detection. These insights could aid the development of more potent, more stable LNP therapeutics."
GTxResolve Premier SEC Columns are engineered to reduce problematic non-specific binding, minimize mobile phase method development challenges, and provide higher throughput separation efficiency. They offer up to 50% increases in resolution for components present within mRNA, LNPs, and viral vector samples. They offer low out-of-the-box secondary interactionsi, iii,&nbsp;iv, enabling robust multi-attribute platform methods and more than 2x improvements in sample consumption, run times, and sensitivity versus existing 5 and 10 µm HPLC columns.v&nbsp; &nbsp;
Waters GTxResolve Premier SEC 1000Å 3 µm Columns are now available globally, alongside Waters previously released GTxResolve Premier BEH&nbsp;SEC 450Å 2.5 µm Columns. These column technologies are quality control batch-tested with an industry-first use of both protein and nucleic acid test mixtures to ensure new levels of separation reproducibility.

Waters Accelerates The Development Of Gene-based Therapeutics With New GTxResolve Premier SEC Columns

<ul>
<li>New Alliance&trade; iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to&nbsp;40%&nbsp;of common errorsi.</li>
<li>Featuring MaxPeak&trade; High Performance Surface (HPS) Technology, the new system minimizes unwanted analyte interactions to increase resolution and sensitivity while reducing peak tailing for metal-sensitive analytes.</li>
<li>Next-generation system delivers a new level of simplicity and instrument intelligence to biologics QC analyses, helping laboratories meet quality, compliance, and on-time product delivery goals.</li>
</ul>

Waters Corporation Unveils Alliance iS Bio HPLC System To Help Biopharma QC Labs Increase Efficiency And Reduce Errors

Throughout the last three months, 4 analysts have evaluated Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Waters and provided 12-month price targets. The average target is $311.25, accompanied by a high estimate of $340.00 and a low estimate of $275.00. Witnessing a positive shift, the current average has risen by 11.66% from the previous average price target of $278.75.
<img src="https://www.benzinga.com/files/images/story/2024/1712264432_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$340.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$330.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$275.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Waters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Waters's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Waters's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Get to Know Waters Better</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
<h3>Waters: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Waters's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -4.55%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Waters's net margin excels beyond industry benchmarks, reaching 26.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.74%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.12, Waters faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For Waters

Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a In-Line and raises the price target from $320 to $340.

Price Target

Evercore ISI Group Maintains In-Line on Waters, Raises Price Target to $340

Goldman Sachs analysts are identifying a substantial opportunity in the manufacturing sector for new obesity therapeutics as demand escalates <a href="https://www.benzinga.com/topic/weight-loss">for these treatments</a>.
Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it could expand up to $400 billion.
Dominant market players like Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) conduct much of their production in-house but are expected to increasingly outsource this business unit to meet the burgeoning demand for weigh-loss medications.
&#8220;We estimate the long term potential market size for GLP-1 manufacturing is ~$10bn and the role of outsourcing will likely increase with volumes.&#8221;
Despite the current dominance of Eli Lilly and Novo Nordisk in the obesity treatment market, Goldman Sachs believes &#8220;increasing volumes along with new entrants into the space will lead to about 50% outsourcing and a about $5bn opportunity for outsourced providers in 2030.&#8221; Both companies have announced capacity expansions to meet growing demand.
According to Goldman Sachs, Eli Lilly&#8217;s tirzepatide, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is forecasted to achieve around $55 billion in sales by 2030, potentially becoming one of the best-selling pharmaceuticals ever.
<h3 class="wp-block-heading">7 Biotech Stocks Benefiting From Obesity Drug Outsourcing Opportunity</h3>
<ul>
<li>Avantor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>): Avantor is poised to benefit from the surge in demand, especially for oral tablet active pharmaceutical ingredients (APIs), as Goldman Sachs anticipates 45% of GLP-1 drugs will be orally administered by 2030. The focus will shift towards API synthesis (upstream) over fill and finish services (downstream).</li>
<li>Thermo Fisher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): Thermo Fisher, already involved in fill and finish services for Novo Nordisk, is expected to see growth in its contract development and manufacturing organization (CDMO) business due to increasing GLP-1 production demands.</li>
<li>Water Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) and Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>): Both companies could gain from the need for more high-performance liquid chromatography (HPLC) instruments and columns as production scales up.</li>
<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>): Danaher is noted to benefit from the entire production chain for biologically produced GLP-1 drugs, which require more upstream solutions like cell lines and culture media.</li>
<li>Wuxi AppTec Co. Ltd (OTCPK: WUXIF): As of August 2023, Wuxi AppTec was a key CDMO for 11 GLP-1 drugs, including clinical and commercial-stage projects, indicating a strong position in the market.</li>
<li>Asymchem Laboratories: Specializing in small molecule drug manufacturing, Asymchem is actively engaged in developing leading oral GLP-1 programs, positioning it well in the growing market.</li>
</ul>
Read Now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37663625/royal-caribbean-carnival-cruise-toward-the-next-wave-of-the-rising-tide-goldman-sac">Royal Caribbean, Carnival Cruise Toward &#8216;The Next Wave of the Rising Tide&#8217;: Goldman Sachs</a>
Photo via Shutterstock.

4 analysts have expressed a variety of opinions on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Waters, presenting an average target of $301.25, a high estimate of $330.00, and a low estimate of $275.00. Witnessing a positive shift, the current average has risen by 13.68% from the previous average price target of $265.00.
<img src="https://www.benzinga.com/files/images/story/2024/1707760821_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Waters among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$330.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$275.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Waters's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Waters's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Discovering Waters: A Closer Look</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
<h3>Unraveling the Financial Story of Waters</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Waters's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 15.14%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 21.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.74%, the company showcases effective utilization of assets.
Debt Management: Waters's debt-to-equity ratio surpasses industry norms, standing at 2.05. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Waters Through 4 Analysts

Waters Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) shares are&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n36951292/waters-corporation-nyse-wat-reports-fourth-quarter-and-full-year-2023-financial-results" rel="noreferrer noopener">trading higher on Tuesday.</a>
The company reported fourth-quarter full-year 2023 sales of $819.47 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus of $815.03 million</a>.
Quarterly revenues declined 4.5%, as reported, and 8% in organic constant currency.
The company reported adjusted earnings per share of $3.62,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">beating the Wallstreet estimate of $3.55.</a>
Gross margin expanded 170 basis points and adjusted operating margin extended 120 basis points in the quarter under review.
&#8220;We have made very good progress integrating the team, achieving our target sales contribution of 2.5% for the year,&#8221; said Udit Batra, President &amp; CEO, Waters Corporation.
Geographically, sales in Asia during the quarter decreased by 18%, as reported, and 16% in organic constant currency (with China sales declining almost 40%).&nbsp;
Sales in the Americas increased by 4% as reported, and decreased 2% in organic constant currency.&nbsp;
Sales in Europe increased by 3%, as reported, and decreased by 6% in organic constant currency.
Outlook:&nbsp;Waters Corp. expects full-year 2024 organic constant currency sales growth to be -0.5% to +1.5%.
The company forecasts reported sales growth of 0% to +2%, with adjusted EPS of $11.75-$12.05 (estimate: $11.97).
Waters Corp projects first quarter organic constant currency sales growth of -11% to -9%. For the first quarter, the company projects reported sales growth of -8.5% to -6.5%, with adjusted EPS of $2.05-$2.15 (estimate: $2.39).
Price Action:&nbsp;WAT shares are trading higher by 1.88% to $330.96 on the last check Tuesday.

Waters Corp Expects Q1 Organic Constant Currency Sales Growth Of -11% To -9%, Reported Sales Growth Of -8.5% To -6.5%; Adj EPS Of $2.05-$2.15 (Est $2.39)

Waters Corp. Expects Full-Year 2024 Organic Constant Currency Sales Growth To Be -0.5% To +1.5%; Reported Sales Growth Of 0% To +2%; Ad EPS Of $11.75-$12.05 (Est. $11.98)

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly Adj. earnings of $3.62 per share which beat the analyst consensus estimate of $3.55 by 1.97 percent. This is a 5.73 percent decrease over earnings of $3.84 per share from the same period last year. The company reported quarterly sales of $819.47 million which beat the analyst consensus estimate of $815.03 million by 0.55 percent. This is a 4.55 percent decrease over sales of $858.51 million the same period last year.

Waters Q4 Adj EPS $3.62 Beats $3.55 Estimate, Sales $819.47M Beat $815.03M Estimate

AEIS

AGCO

AMCR

AMGN

AMRK

AOSL

ARCB

ARMK

ARWR

ASTL

ATEN

ATHM

AUDC

AVNW

AZEK

AZPN

CARR

CEIX

CHKP

CINF

CRNC

CRUS

CTSH

DCPH

DIOD

ENPH

EXEL

FRSH

FTNT

GAIN

GEHC

GILD

HIMX

HLNE

ICHR

INGR

INNV

INSP

INTA

JKHY

KREF

KTCC

LPTV

LSAK

LUMN

MODN

MRCY

MSGS

MSTR

PLUS

QGEN

Earnings Scheduled For February 6, 2024

Analysts' ratings for Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waters, revealing an average target of $271.67, a high estimate of $300.00, and a low estimate of $230.00. A decline of 0.3% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1706205620_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Waters. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$275.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$230.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$290.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Timothy Daley</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Waters's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waters's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>About Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
<h3>A Deep Dive into Waters's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Waters displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 0.44%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Waters's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 2.97%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.86, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Waters

Barclays analyst Luke Sergott maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Underweight and raises the price target from $230 to $275.

Barclays Maintains Underweight on Waters, Raises Price Target to $275

Wolfe Research analyst Doug Schenkel initiates coverage on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Waters with Peer Perform Rating

Over the past 3 months, 7 analysts have published their opinion on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
These 7 analysts have an average price target of $270.71 versus the current price of Waters at $292.14, implying downside.
Below is a summary of how these 7 analysts rated Waters over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1702299645_0.png" alt="price target chart" />
This current average represents a 4.17% decrease from the previous average price target of $282.50. 
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h1>What Are Analyst Ratings?</h1>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Waters Stands With Analysts

Citigroup analyst Patrick Donnelly maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $265 to $300.

Citigroup Maintains Neutral on Waters, Raises Price Target to $300

Waters Inaugurated Its New Global Capability Center In A Newly Built Facility In Bengaluru's RMZ Ecoworld Technology Park, The New $16M Workspace Will Employ 300+ For Roles That Were Formerly Outsourced

U.S. stocks traded lower, with the Dow Jones falling around 90 points on Tuesday. Shares of Agilent Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/a#NYSE">A</a>) jumped during Tuesday&rsquo;s session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/23/11/35887848/how-to-earn-500-a-month-from-agilent-technologies-stock-following-upbeat-results">fourth-quarter financial results</a>.
Agilent reported quarterly earnings of $1.38 per share, surpassing the analyst consensus estimate of $1.35. The company reported quarterly sales of $1.69 billion, which beat analyst expectations of $1.68 billion, according to data from <a href="http://pro.benzinga.com/">Benzinga Pro.</a>
Agilent said it sees full-year 2024 earnings between $5.44 and $5.55 per share, versus the $5.61 estimate. The company expects full-year revenue between $6.71 billion and $6.81 billion, versus the $6.98 billion estimate.
Agilent Technologies jumped 8.3% to $123.43 on Tuesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Symbotic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sym#NASDAQ">SYM</a>) shares surged 23.8% to $46.02 after the company reported better-than-expected fourth-quarter sales results.</li>
<li>Burlington Stores, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/burl#NYSE">BURL</a>) jumped 19% to $162.77 after the company reported third-quarter financial results and issued guidance.</li>
<li>Hibbett, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hibb#NASDAQ">HIBB</a>) shares rose 14.7% to $61.55 following strong quarterly sales.</li>
<li>Dycom Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dy#NYSE">DY</a>) surged 14.5% to $99.35 following better-than-expected third-quarter results.</li>
<li>Artivion, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aort#NYSE">AORT</a>) shares gained 13% to $15.95. Artivion recently announced completion of enrollment in PERSEVERE trial.</li>
<li>Caleres, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cal#NYSE">CAL</a>) rose 12.8% to $31.02 following strong quarterly earnings.</li>
<li>DICK&#39;S Sporting Goods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) gained 10.8% to $131.88 after the company reported a year-over-year increase in third-quarter revenues and raised its 2023 guidance.</li>
<li>Telecom Argentina S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/teo#NYSE">TEO</a>) gained 10.5% to $7.22.</li>
<li>Pulse Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plse#NASDAQ">PLSE</a>) climbed 9.1% to $6.83. Pulse Biosciences filed 510(k) submission with US FDA for its CellFX nsPFA Percutaneous Electrode.</li>
<li>Golden Ocean Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gogl#NASDAQ">GOGL</a>) rose 8.8% to $8.52 following quarterly results.</li>
<li>Fusion Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fusn#NASDAQ">FUSN</a>) climbed 8% to $4.8150.</li>
<li>VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) gained 7.7% to $5.77 after Wedbush initiated coverage on the stock with an Outperform rating and $12 price target.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) climbed 6.7% to $2.7316.</li>
<li>Waters Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wat#NYSE">WAT</a>) gained 5.8% to $276.20.</li>
<li>Mettler-Toledo International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtd#NYSE">MTD</a>) climbed 5.2% to $1,104.57.</li>
<li>Gen Digital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gen#NYSE">GEN</a>) shares rose 4.6% to $21.74 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/35887848/how-to-earn-500-a-month-from-agilent-technologies-stock-following-upbeat-results"> How To Earn $500 A Month From Agilent Technologies Stock Following Upbeat Results</a>

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/17/23</td>
<td>$140.00</td>
<td>$293.7K</td>
<td>9.4K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MOR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/19/24</td>
<td>$10.00</td>
<td>$48.1K</td>
<td>15.3K</td>
<td>737</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/19/24</td>
<td>$102.50</td>
<td>$300.0K</td>
<td>248</td>
<td>600</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/24/23</td>
<td>$600.00</td>
<td>$34.8K</td>
<td>834</td>
<td>565</td>
</tr>
<tr>
<td>MRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/15/24</td>
<td>$45.00</td>
<td>$30.0K</td>
<td>662</td>
<td>500</td>
</tr>
<tr>
<td>WAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/17/23</td>
<td>$250.00</td>
<td>$118.1K</td>
<td>874</td>
<td>363</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$50.00</td>
<td>$33.2K</td>
<td>395</td>
<td>354</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/15/23</td>
<td>$540.00</td>
<td>$34.0K</td>
<td>2.9K</td>
<td>321</td>
</tr>
<tr>
<td>IMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$17.00</td>
<td>$52.1K</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>NTLA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$40.00</td>
<td>$35.0K</td>
<td>590</td>
<td>120</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option trade that happens to be neutral, is expiring today. Parties traded 1329 contract(s) at a $140.00 strike. The total cost received by the writing party (or parties) was $293.7K, with a price of $221.0 per contract. There were 9491 open contracts at this strike prior to today, and today 1402 contract(s) were bought and sold. 
• Regarding MOR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>), we observe a call option sweep with bearish sentiment. It expires in 63 day(s) on January 19, 2024. Parties traded 292 contract(s) at a $10.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $165.0 per contract. There were 15342 open contracts at this strike prior to today, and today 737 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a put option trade with bullish sentiment. It expires in 63 day(s) on January 19, 2024. Parties traded 600 contract(s) at a $102.50 strike. The total cost received by the writing party (or parties) was $300.0K, with a price of $500.0 per contract. There were 248 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 7 day(s) on November 24, 2023. Parties traded 50 contract(s) at a $600.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $34.8K, with a price of $699.0 per contract. There were 834 open contracts at this strike prior to today, and today 565 contract(s) were bought and sold. 
• For MRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTX#NASDAQ">MRTX</a>), we notice a put option trade that happens to be bearish, expiring in 119 day(s) on March 15, 2024. This event was a transfer of 500 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $60.0 per contract. There were 662 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For WAT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 93 contract(s) at a $250.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $118.1K, with a price of $1270.0 per contract. There were 874 open contracts at this strike prior to today, and today 363 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a call option trade with bearish sentiment. It expires in 154 day(s) on April 19, 2024. Parties traded 14 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $2376.0 per contract. There were 395 open contracts at this strike prior to today, and today 354 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bullish sentiment. It expires in 28 day(s) on December 15, 2023. Parties traded 40 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $850.0 per contract. There were 2925 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding IMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>), we observe a call option sweep with neutral sentiment. It expires in 791 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $17.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $52.1K, with a price of $490.0 per contract. There were 150 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding NTLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), we observe a call option trade with bearish sentiment. It expires in 308 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $350.0 per contract. There were 590 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

DXCM

IMGN

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRTX

NTLA

10 Health Care Stocks With Whale Alerts In Today's Session

InvestorsObserver is giving Waters Corp (WAT) an Analyst Rating Rank of 5, meaning WAT is ranked higher by analysts than 5% of stocks. The average price target for WAT is $305.769 and analystâ€&#x2122;s rate the stock as a Hold. Wall Street analysts are rating WAT a Hold today.  Find out what this means to you and get the rest of t

Analyst Rating: Will Waters Corp (WAT) Stock Do Better Than the Market?

InvestorsObserver is giving Waters Corp (WAT) an Analyst Rating Rank of 5, meaning WAT is ranked higher by analysts than 5% of stocks. The average price target for WAT is $305.769 and analyst's rate the stock as a Hold. Wall Street analysts are rating WAT a Hold today.  Find out what this means to you and get the rest of t

Overall market sentiment has been neutral on Waters Corp (WAT)  stock lately. WAT receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator. Waters Corp has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on WAT!See Full WAT ReportWhat is Stock Sentiment?Senti

Should You Buy Waters Corp (WAT) Stock on Wednesday?

Waters Corp (WAT) is near the middle in its industry group according to InvestorsObserver. WAT gets an overall rating of 45. That means it scores higher than 45 percent of stocks. Waters Corp gets a 66 rank in the Diagnostics and Research industry. Diagnostics and Research is number 88 out of 148 industries. WAT has an Ove

Is Waters Corp (WAT) a Smart Choice in Diagnostics & Research Thursday?

The most shorted S&P 500 stocks as a percentage of float - BofA

S&P 500 stocks with the lowest hedge fund net exposure - BofA

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Waters (WAT – Research Report) and UnitedHealth (UNH – Research R...

Analysts Offer Insights on Healthcare Companies: Waters (WAT) and UnitedHealth (UNH)

Barclays analyst Luke Sergott maintained a Sell rating on Waters (WAT – Research Report) today and set a price target of $300.00. The company's sha...

Barclays Remains a Sell on Waters (WAT)

Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March

Danaher gains as Q1 results exceed expectations

CHRW

CHTR

ETSY

FOXA

MRNA

NCLH

PARA

POOL

RGEN

TROW

TSCO

ZION

Press Releases

Waters Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Commodities

Waters Corporation Schedules Fourth Quarter 2023 Earnings Conference Call

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2023 Financial Results

Waters Corporation to Present at the TD Cowen 44th Annual Health Care Conference

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

Waters Advances Battery Electrode Design and Performance Analysis with New Rheo-IS Accessory

Waters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

Waters Corporation Schedules First Quarter 2024 Earnings Conference Call

Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns